Most Read Articles
4 days ago
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Roshini Claire Anthony, 6 days ago

Frailty may indicate an increased risk of death from COVID-19, results of the COPE* study showed.

6 days ago
Regardless of treatment, serum hepcidin is elevated in patients with restless leg syndrome (RLS) and may act as a biomarker for this condition, a recent study has found.
Jairia Dela Cruz, 2 days ago
In the first year following percutaneous coronary intervention for acute coronary syndrome, ticagrelor and prasugrel cuts the risk of gastrointestinal (GI) bleeding by more than 30 percent compared with clopidogrel, as shown in a large real-world study.

JAK inhibitors for immune-mediated diseases may increase herpes zoster risk

21 May 2020

The use of Janus kinase (JAK) inhibitors for the treatment of inflammatory bowel diseases (IBDs) and other immune-mediated diseases may increase the risk of herpes zoster infection, reports a recent meta-analysis.

Accessing the databases of the Cochrane Central Register of Controlled Trials, Embase and Medline, researchers retrieved 82 studies corresponding to 66,159 patients with immune-mediated diseases. Most of the enrolled papers were randomized controlled trials. The primary study outcome was the incidence of adverse events.

Forty-four studies investigated the effect of treatment on herpes zoster infection risk, most of which used tofacitinib (n=26), though there were also reports on baricitinib, filgotinib and upadacitinib. In the pooled sample of 48,093 patients, the incidence rate of herpes zoster was 2.11 per 100 patient-years. Among treated comparators, the corresponding rate was 1.23 per 100 patient-years.

This resulted in a significant excess in risk estimate (risk ratio [RR], 1.57, 95 percent CI, 1.04–2.37), which persisted even when limiting analysis to placebo-controlled studies (RR, 1.72, 95 percent CI, 1.07–2.76). Heterogeneity was insignificant.

No such differences in risk were found for other adverse outcomes, including serious infections, malignancies and major cardiovascular events. Mortality was likewise comparable among treatment groups (RR, 0.72, 95 percent CI, 0.40–1.28).

“More studies with long follow-up and in the real-world setting in the different conditions will be needed to fully elucidate the safety profile of the different JAK inhibitors,” the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Roshini Claire Anthony, 6 days ago

Frailty may indicate an increased risk of death from COVID-19, results of the COPE* study showed.

6 days ago
Regardless of treatment, serum hepcidin is elevated in patients with restless leg syndrome (RLS) and may act as a biomarker for this condition, a recent study has found.
Jairia Dela Cruz, 2 days ago
In the first year following percutaneous coronary intervention for acute coronary syndrome, ticagrelor and prasugrel cuts the risk of gastrointestinal (GI) bleeding by more than 30 percent compared with clopidogrel, as shown in a large real-world study.